Finasteride

Drug Profile

Finasteride

Alternative Names: Anatine; Andozac; Avertex; Chibro-Proscar; Eutiz; Finasterin; Finastid; Jacarin; MK-0906; MK-906; Nasteril; Penester; Pro-Cure; Prodel; Propecia; Proscar; Prostene; Prosterid; Prostide; Tealep; YM-152

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Androstenes; Antiacnes; Antiandrogens; Antineoplastics; Azasteroids; Small molecules
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alopecia; Benign prostatic hyperplasia
  • No development reported Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 May 2015 No recent reports of development identified - Phase-III for Prostate cancer (Prevention) in Canada and USA (PO)
  • 05 Feb 2014 MSD Korea and Hanmi Pharmaceutical agree to co-promote finasteride in South Korea for Alopecia and Benign prostatic hyperplasia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top